Taken together, these data implicate hyperinsulinemia as a key pathogenic factor in the progression of both breast and colon cancer in two mouse models and identify SGLT2 inhibition as a potential means of slowing obesity-associated cancer progression in vivo. Here, SLC5A2 is linked to colonic neoplasm.